coup-tfii inhibits tgf-beta-induced growth barrier promote prostate tumorigenesis
mutations phosphatase tensin homologue pten genomic alterations phosphatidylinositol--oh kinase-signalling pathway common genetic alterations reported human prostate cancer- however precise mechanism underlying indolent tumours pten alterations acquire metastatic potential remains poorly understood recent studies suggest upregulation transforming growth factor tgf-beta signalling triggered pten loss will form growth barrier defence mechanism constrain prostate cancer progression underscoring tgf-beta signalling might represent pre-invasive checkpoint prevent pten-mediated prostate tumorigenesis show coup transcription factor ii coup-tfii also known nr2f2- member nuclear receptor superfamily serves key regulator inhibit smad4-dependent transcription consequently overrides tgf-beta-dependent checkpoint pten-null indolent tumours overexpression coup-tfii mouse prostate epithelium cooperates pten deletion augment malignant progression produce aggressive metastasis-prone tumour functional counteraction coup-tfii smad4 reinforced genetically engineered mouse models conditional loss smad4 diminishes inhibitory effects elicited coup-tfii ablation biological significance coup-tfii prostate carcinogenesis substantiated patient sample analysis coup-tfii expression activity tightly correlated tumour recurrence disease progression whereas inversely associated tgf-beta signalling findings reveal destruction tgf-beta-dependent barrier coup-tfii crucial progression pten-mutant prostate cancer life-threatening disease supports coup-tfii potential drug target intervention metastatic human prostate cancer
